Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Biomolecules. 2022 Sep 29;12(10):1397. doi: 10.3390/biom12101397.
The mitochondrial translocator protein (TSPO) is a modulator of the apoptotic pathway involving reactive oxygen species (ROS) generation, mitochondrial membrane potential (Δψm) collapse, activation of caspases, and eventually initiation of the apoptotic process. In this in vitro study, H1299 lung cells and BV-2 microglial cells were exposed to the hypoxia-like effect of CoCl2 with or without PK 11195. Exposing the H1299 cells to 0.5 mM CoCl2 for 24 h resulted in decreases in cell viability (63%, p < 0.05), elevation of cardiolipin peroxidation levels (38%, p < 0.05), mitochondrial membrane potential depolarization (13%, p < 0.001), and apoptotic cell death (117%, p < 0.05). Pretreatment with PK 11195 (25 µM) exhibited significant protective capacity on CoCl2-induced alterations in the mentioned processes. Exposure of BV-2 cells to increasing concentrations of CoCl2 (0.3, 0.5, 0.7 mM) for 4 h resulted in alterations in the same cellular processes. These alterations were obtained in a dose-dependent manner, except the changes in caspases 3 and 9. The novel ligands as well as PK 1195 attenuated the in vitro hypoxia-like effects of CoCl2. It appears that the TSPO ligand PK 11195 can prevent CoCl2-induced cellular damage in both non-neuronal and brain cell lines, and they may offer a novel approach to the treatment of hypoxia-related lung and brain diseases in some cases that fail to respond to conventional therapies.
线粒体转位蛋白(TSPO)是一种调节细胞凋亡途径的蛋白,涉及活性氧(ROS)的产生、线粒体膜电位(Δψm)的崩溃、半胱天冬酶的激活,最终引发细胞凋亡过程。在这项体外研究中,H1299 肺癌细胞和 BV-2 小胶质细胞分别暴露于 CoCl2 模拟的缺氧环境中或同时暴露于 CoCl2 和 PK 11195 中。将 H1299 细胞暴露于 0.5mM CoCl2 24 小时后,细胞活力降低(63%,p<0.05),心磷脂过氧化水平升高(38%,p<0.05),线粒体膜电位去极化(13%,p<0.001),细胞凋亡增加(117%,p<0.05)。预先用 PK 11195(25µM)预处理对 CoCl2 引起的上述变化具有显著的保护作用。将 BV-2 细胞暴露于递增浓度的 CoCl2(0.3、0.5、0.7mM)4 小时,引起了相同的细胞过程的改变。这些变化呈剂量依赖性,除了半胱天冬酶 3 和 9 的变化。新型配体以及 PK 1195 可减轻 CoCl2 引起的体外缺氧样效应。似乎 TSPO 配体 PK 11195 可以预防 CoCl2 引起的非神经元和脑细胞系的细胞损伤,并且它们可能为某些对传统疗法无反应的与缺氧相关的肺和脑部疾病的治疗提供新的方法。